Moderna's cancer vaccine rally hits a wall as another drugmaker steals the show
FROM THE WIRE · FINANCE.YAHOO.COM
Amgen showcases “excellent” data for its small-cell lung cancer treatment following leaked results for Moderna and Merck’s intismeran autogene. Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralPositive Amgen data in small-cell lung cancer may weigh on competing drugmakers.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Amgen showcased 'excellent' data for its small-cell lung cancer treatment.
- 02The news follows leaked results for Moderna and Merck's intismeran autogene.
- 03Moderna's rally on its cancer vaccine has hit a wall.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Amgen Inc.440.58 USD+0.11%today +0.30%Positive Moderna, Inc.194.30 USD-1.01%today -2.90%Negative Merck & Co., Inc.140.80 USD-0.43%today -3.08%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets